TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03853252

Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy on a location preliminarily anesthetized Disinfection protocol Combined required blood tests (HIV, Hepatitis B)
Study: NCT03953456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elafibranor 120mg
Description: elafibranor 120mg is a coated tablet for oral administration, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: elafibranor 120mg
Description: elafibranor 120mg is a coated tablet for oral administration, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a coated tablet for oral administration, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a coated tablet for oral administration, once daily
Study: NCT02369861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST266
Description: Topical ocular application 4 times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Refresh Lubricant Eye Drops
Description: Topical ocular application 4 timer per day
Study: NCT01333111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode
Study: NCT02161406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 125 mg of Placebo
Study: NCT01969045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enk Fiberoptic Atomizer
Description: Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the felxible bronchoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bronchoscope
Description: Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the felxible bronchoscopy
Study: NCT03990142

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cutaneous conductance to chlorine by SUDOSCAN
Description: The additional examination, related to this research protocol, corresponds to a record of cutaneous conductance with chlorine. This recording of 2 min 30 is done thanks to SUDOSCAN® within 30 minutes before the dialysis session (before the connection to the dialysis machine) and within 30 minutes after the end of the dialysis with a measurement of the tension blood pressure and heart rate immediately before SUDOSCAN®.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cutaneous conductance to chlorine by SUDOSCAN
Description: The additional examination, related to this research protocol, corresponds to a record of cutaneous conductance with chlorine. This recording of 2 min 30 is done thanks to SUDOSCAN® within 30 minutes before the dialysis session (before the connection to the dialysis machine) and within 30 minutes after the end of the dialysis with a measurement of the tension blood pressure and heart rate immediately before SUDOSCAN®.
Study: NCT03937713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: Eszopiclone is a nonbenzodiazepine benzodiazepine receptor agonists, effective for both sleep onset insomnia and sleep maintenance insomnia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief behavioral therapy for insomnia
Description: BBTI is based on the core principles that are fundamental to other empirically-supported behavioral treatments of insomnia delivered over four consecutive weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief behavioral therapy for insomnia
Description: BBTI is based on the core principles that are fundamental to other empirically-supported behavioral treatments of insomnia delivered over four consecutive weeks.
Study: NCT00598871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymosin Beta 4 (Tβ4)
Description: There are 2 groups: active drug and placebo. The patients in the active arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times daily (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of 0.00% Tβ4(w/w) eyedrops to the affected eye, 2 drops four times a day (QID) (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
Study: NCT00619268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 25 mg once per week administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg \* 1 time /2 weeks administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 10 mg/kg \* 1 time /2 weeks administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon alpha-2a
Description: Administered subcutaneously as 9 MU three times per week
Study: NCT02043834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes.
Study: NCT03058380

Intervention type: OTHER
Intervention: Stated-Preferences Evaluation Instrument
Description: A discrete choice experiment (Stated-Preferences Evaluation Instrument) will be electronically configured using best practice stated-preference methods to quantify preferences for total knee replacement versus unicompartmental knee replacement surgery.
Study: NCT04199468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Delta-9-THC
Description: Active Delta-9-THC (0.015 mg/kg) given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Delta-9-THC
Description: Active Delta-9-THC (0.015 mg/kg) given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Delta-9-THC
Description: A placebo dose given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Delta-9-THC
Description: A placebo dose given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Ketamine
Description: Active Ketamine (0.2 mg/kg) given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Ketamine
Description: Active Ketamine (0.2 mg/kg) given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Ketamine
Description: A placebo dose given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Ketamine
Description: A placebo dose given intravenously (IV)
Study: NCT01893853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Exercise intervention trials will consist of a steady-state bout of exercise at \~70% VO2peak and a timed performance test on a cycle ergometer in a heated environment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Intervention
Description: Exercise intervention trials will consist of a steady-state bout of exercise at \~70% VO2peak and a timed performance test on a cycle ergometer in a heated environment.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Intervention
Description: Exercise intervention trials will consist of a steady-state bout of exercise at \~70% VO2peak and a timed performance test on a cycle ergometer in a heated environment.
Study: NCT01983462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03374163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intralipid 20%
Description: milky soulation for energey supplement.
Study: NCT01636089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicarbonates
Description: sodium bicarbonates 1,4%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: sodium chloride 0,9%
Study: NCT03951545

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First line total knee replacement for gonarthrosis .
Description: Patients requiring 1st line total knee replacement for gonarthrosis with a Hip knee angle (HKA) between 170° and 183°. In the first group (Mechanical) the total knee replacement will be performed with a tibial cut by using extramedullary mechanical sighting and in the second group (Gyroscopic) by using gyroscopic and accelerometric navigation (I-Assist).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: First line total knee replacement for gonarthrosis .
Description: Patients requiring 1st line total knee replacement for gonarthrosis with a Hip knee angle (HKA) between 170° and 183°. In the first group (Mechanical) the total knee replacement will be performed with a tibial cut by using extramedullary mechanical sighting and in the second group (Gyroscopic) by using gyroscopic and accelerometric navigation (I-Assist).
Study: NCT01222663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate

Intervention type: DEVICE
Group type: OTHER
Intervention: standard therapy
Description: Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoperfusion
Description: Extracorporeal hemoperfusion with Toraymyxin PMX-20R and conventional medical therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate.
Study: NCT00516490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin acetate
Description: Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Na Cl %0.9
Description: 0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer
Study: NCT05063526

Intervention type: DEVICE
Intervention: ultrasound
Description: ultrasound on diaphragm

Intervention type: DEVICE
Intervention: ultrasound
Description: ultrasound on diaphragm

Intervention type: DEVICE
Intervention: ultrasound
Description: ultrasound on diaphragm
Study: NCT02963272

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional strategy
Description: Conventional strategy to manage the patients with HF, following the international guidelines.

Intervention type: OTHER
Group type: OTHER
Intervention: ST2-guided strategy
Description: patients wit ST2 over the median are targeted with higher doses of drugs with putative effects on fibrosis and anti HF pathophysiology
Study: NCT00523809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg IV Daily Over 30 Minutes for 1 Day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Stem Cell Transplantation on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 IV Daily Over 30 Minutes for 5 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2 IV Daily Over 30 Minutes for 2 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1.
Study: NCT00429650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: increased exercise
Description: Use prescribed number of minutes of exercise 5-6 days per week to maintain weight loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet
Description: Use a prescribed diet to maintain weight loss

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Diet
Description: Use a combination of exercise and diet to maintain weight loss.
Study: NCT04659317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone 5 mg Oral Tablet
Description: Encapsulated Oxycodone 5 mg tablets x24, to take po q6 hours as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Encapsulated placebo tablets x24, to take po q6 hours as need for pain
Study: NCT00747253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoLITT system
Description: laser treatment with the AutoLITT system
Study: NCT00262002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation)
Description: MenACWY-CRM conjugate vaccine formulated without adjuvant was injected IM (intramuscularly) in the anterolateral area of the right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation)
Description: MenACWY-CRM conjugate vaccine formulated without adjuvant was injected IM (intramuscularly) in the anterolateral area of the right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)
Description: MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)
Description: MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)
Description: MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)
Description: MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)
Description: MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY PS (MenACWY-CRM, polysaccharide vaccine)
Description: MenACWY polysaccharide vaccine was injected in the anterolateral area of the right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY PS (MenACWY-CRM, polysaccharide vaccine)
Description: MenACWY polysaccharide vaccine was injected in the anterolateral area of the right thigh.
Study: NCT01605786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilised PEBS synthetic protein (PfPEBS)
Description: PfPEBS, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131 aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 5μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilised PEBS synthetic protein (PfPEBS)
Description: PfPEBS-LSP, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 30 μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehydragel™ HPA
Description: Aluminium hydroxide adjuvant is being used as the adjuvant for the vaccine and will be used as the comparator in the control group. Vac4all is using Rehydragel™ (Manufacturer Reheis Inc.) which is a highly active protein adsorbent specially compounded for use as a fluid adjuvant. It has low oxide content and is carefully controlled for Al2O3 content and protein binding capacity. It has a lower viscosity than competing adjuvants, which makes it easier to process and handle.~Subjects in the control group will be administered a 0.5 ml injection in a 2-dose schedule at 28 days interval. Each injection will contain approximately 600 µg of Al(OH)3 per injected dose corresponding to 200 µg equivalent of Al3+, similar to the amount being administered in the vaccine group.
Study: NCT00684203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: 100 mg two or three times daily for 60 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 100 mg two or three times daily for 60 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 100 mg two or three times daily for 60 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 100 mg two or three times daily for 60 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 100 mg two or three times daily for 60 days.
Study: NCT00248534

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: given IV days 1,8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 2hr IV every 28 days post consolidation cycles of Temozolomide (TMZ) (6 cycles TMZ = Consolidation cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Induction Days 1-7 and 15-21 (150mg/m2 PO) Consolidation days 1-5 every 28 days X 6 cycles
Study: NCT04077385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval-extinction (R-E) Training
Description: The retrieval-extinction (R-E) training intervention will occur on two consecutive days and consist of (a) retrieval of high calorie food cue-reward associative memories and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 high calorie food images (e.g., cakes, cookies, muffins, hamburgers, french fries, potato chips, pizza). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion of high calorie snack foods such as a single M\&M or potato chip.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extinction Training
Description: The extinction control group will engage in two consecutive days of intervention consisting of (a) retrieval of memories not associated with high calorie foods and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 non-food-related neutral images (e.g., office supplies, tools). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion of high calorie snack foods such as a single M\&M or potato chip. The 60-min extinction training is the same as the extinction training received by participants in the R-E training intervention.
Study: NCT01699698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor markers
Description: Duodenal juice are collected using endoscope and cannula. Tumor markers of collected samples are analyzed. The marker concentration is applied to statistical analysis.